On March 4, aetherAI Chairman Dr. Joe Yeh pointed out that while the technical barriers for Medical AI have lowered, the true bottleneck lies in institutional and market maturity. For Pathology AI to succeed, it must be integrated into diagnostic guidelines by medical societies, aligned with hospital annual budgets, and supported by stable cash-flow models.

aetherAI passed its listing review for the Taiwan Innovation Board (TIB) at the end of last year and expects to go public in H1 2026. Its shareholder structure is notable, with Quanta Computer holding 15%, alongside Cathay Venture and CDIB Capital, bringing total institutional ownership to approximately 25%.

• Market Leadership: aetherAI holds a 70% market share among Taiwanese hospitals that have digitized their pathology departments, including major medical centers like Chang Gung, NTU, TVGH, and Mackay.
• International Expansion: Revenue reached NT$193 million in 2025 (a 91.9% YoY increase), with nearly half contributed by overseas markets. The company has successfully entered elite university hospital systems in Germany (Tübingen, Frankfurt, and Aachen) and Japan, competing directly with giants like Philips, Sectra, and Proscia.
• Business Model: Dr. Yeh emphasized that "point-solution" AI models are risky and difficult to monetize. Instead, aetherAI uses its Digital Pathology Image Management Platform to secure recurring revenue, using AI as an engine for long-term value. The company also utilizes the LDTs (Laboratory Developed Tests) model for greater flexibility compared to the 2-3 year traditional medical device regulatory pathway.

Resource: 雲象拚平台化突圍病理AI商機 葉肇元：制度成熟度才是商業化關鍵